Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Status: Completed
Location: See all (40) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage.
• Have adequate organ function.
• Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.
• Have discontinued previous treatments for cancer.
• Are able to swallow capsules.
Locations
United States
Arkansas
Highlands Oncology Group
Fayetteville
Colorado
Rocky Mountain Cancer Center
Denver
Florida
H Lee Moffitt Cancer Center
Tampa
Massachusetts
Dana Farber Cancer Institute
Boston
Massachusetts General Hospital
Boston
Missouri
Washington University Medical School
Saint Louis
North Carolina
Levine Cancer Institute- Carolinas Medical Center
Charlotte
New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon
New York
Memorial Sloan Kettering Cancer Center
New York
Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh
South Carolina
Prisma Health Cancer Institute
Greenville
Texas
Texas Oncology Cancer Center
Austin
Texas Oncology Fort Worth
Fort Worth
University of Texas MD Anderson Cancer Center
Houston
US Oncology
The Woodlands
Tyler Cancer Center
Tyler
Other Locations
Belgium
Grand Hopital de Charleroi-Site Notre-Dame
Charleroi
Universitair Ziekenhuis Gent
Gent
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven
AZ Delta
Roeselare
France
Institut Bergonie
Bordeaux
Centre Georges Francois Leclerc
Dijon Cedex
Centre de Lutte Contre le Cancer Leon Berard
Lyon Cedex 08
APHM Hôpital de la Timone
Marseille
Institut Curie
Paris Cedex 05
Institut de Cancérologie de l'Ouest Centre René Gauducheau
Saint Herblain Cedex
Japan
National Cancer Center Hospital
Chuo-ku
Republic of Korea
Asan Medical Center
Seoul
Samsung Medical Center
Seoul
Severance Hospital Yonsei University Health System
Seoul
Spain
Hospital Universitari Vall d'Hebron
Barcelona
Institut Catala d'Oncologia
L'hospitalet De Llobregat
Hospital Universitario 12 de Octubre
Madrid
Hospital Universitario Ramon y Cajal
Madrid
Hospital Clinico Universitario Virgen de la Victoria
Malaga
Hospital Universitario La Fe de Valencia
Valencia
Turkey
Dr.Abdurrahman Yurtaslan Ankara Oncology Training & Res Hosp
Ankara
Ege University Faculty of Medicine
Izmir
United Kingdom
Guys/St. Thomas Hospital
London
Royal Marsden Hospital
Sutton
Time Frame
Start Date: 2019-07-16
Completion Date: 2021-03-30
Participants
Target number of participants: 48
Treatments
Experimental: LY3295668 Erbumine Cohort A
LY3295668 erbumine administered orally.
Experimental: LY3295668 Erbumine Cohort B
LY3295668 erbumine administered orally.
Experimental: LY3295668 Part JP
LY3295668 erbumine administered orally.
Authors
Óscar Juan Vidal, Konstantin Dragnev, Timothy F Burns, Lauren Byers, Eric S Schaefer, Jacob Sands, Anna F Farago, Donald A Richards, Kathryn Mileham, Stephen L Richey, Siddhartha Devarakonda, Nicolas ISAMBERT, Fabrice Barlesi, Alice Hervieu, Meenali Chitnis, Eleni Karapanagiotou, Laurent Greillier, Philippe CASSIER, Judith Raimbourg, Antoine Italiano, Deepa Rangachari, Robert Jotte, Alberto Chiappori, Karen Reckamp, Omur Berna Oksuzoglu, Alejandro Navarro, Veerle Surmont, Catherine Daniel, Anna Minchom, Maria Eugenia Olmedo, Noboru Yamamoto, Tuncay Goksel, Umut Demirci, Jean-Luc Canon, Keunchil Park, Ingel Demedts, Sang-We Kim, Byoung Chul Cho
Related Therapeutic Areas
Sponsors
Leads: Eli Lilly and Company